🌍 Planetterrian Daily - Science, Longevity & Health Discoveries
| Researchers identified claudin-4 as the receptor that lets a common gut bacterium toxin damage colon cells and promote tumors. |
Top 12 Science & Health Discoveries
- Gut bacterium toxin uses claudin-4 to damage colon lining — Nature via Science Daily
A team at Johns Hopkins Kimmel Cancer Center used CRISPR genome-wide screening on colon epithelial cells to find that disabling the gene for claudin-4 prevented Bacteroides fragilis toxin from binding. The toxin normally disrupts E-cadherin after docking at claudin-4, which maintains tight junctions between cells. Structural biologists confirmed a direct complex forms between BFT and claudin-4. A molecular decoy built from this interaction protected mice from toxin damage in tests. The bacterium resides in roughly 20 percent of healthy people, and only certain strains produce the toxin linked to inflammation and tumors. Earlier work from the same group in 2009 had already linked toxin-producing strains to colon tumor formation through chronic inflammation. Maxwell White led the CRISPR screen in collaboration with Matthew Waldor’s laboratory at Harvard Medical School. Senior author Cynthia Sears noted that identifying the receptor opens routes to new detection and therapy strategies for diarrhea, colorectal cancer, and bloodstream infections. Source: sciencedaily.com - Cancer can start from epigenetic change without driver mutations — r/longevity
A study on YAP1 in hepatocellular carcinoma showed the protein induces tumors through DNA demethylation rather than canonical gene mutations. The finding broadens understanding of how tumors form when mutation-driven pathways are absent. Researchers submitted the work highlighting that epigenetic mechanisms alone can drive liver cancer initiation. The result challenges assumptions that driver gene mutations are always required for hepatocellular carcinoma development. Source: reddit.com - New cholesterol pathway involves Ral protein and cathepsin A enzyme — Nature via Science Daily
UC San Diego researchers found that high dietary cholesterol activates the Ral protein in liver cells, which then triggers cathepsin A to reduce LDL receptors. Blocking cathepsin A with a small-molecule inhibitor stabilized the receptors and lowered circulating LDL in mice. An existing CTSA inhibitor that already passed human safety testing could move to phase 2 trials for cholesterol lowering. Senior author Alan Saltiel explained that the liver normally clears LDL cholesterol through LDL receptors on cell surfaces. The newly traced route operates independently of statins and PCSK9 inhibitors. Experiments combined mouse models with human cell studies to map how Ral activity leads to receptor loss. The inhibitor had previously been evaluated in a Phase 1 trial for heart failure before that program ended. Source: sciencedaily.com - Giant virus carries tandem potassium channel gene from host — Phys.org
Researchers identified a gene for a tandem potassium channel inside an algal virus genome. The discovery supports the idea that giant viruses have transferred genes that helped build complex membrane proteins in early eukaryotes. The work appears in Proceedings of the National Academy of Sciences. The finding adds evidence that viruses contributed to the evolution of sophisticated ion channels still used by modern cells. Source: phys.org - Fossil shows first dinosaur specialized for eating fruit — Phys.org
Paleontologists described Infernogallus jamesi, a small oviraptorosaur whose jaw muscles were adapted for mashing soft fruit. The Cretaceous find from North Dakota marks the earliest known dinosaur with this feeding strategy tied to the rise of flowering plants. The species belongs to a group of small, feathered dinosaurs that lived alongside early angiosperms. Jaw muscle reconstruction revealed adaptations for processing soft, energy-rich plant material rather than harder vegetation or meat. Source: phys.org - Molecular cage traps planar molecules like a lock — Phys.org
Chemists linked two curved π-conjugated molecules at three points to create an internal cavity that selectively binds shape-matched planar guests. The design offers a new route to host-guest chemistry for sensing or separation. The cage forms through precise face-to-face connection that creates a defined space inside the structure. Researchers demonstrated binding specificity for molecules with matching flat geometry. Source: phys.org - Citizen science project tracks microbats with detectors — Phys.org
Volunteers use ultrasonic detectors after dark to record echolocation calls and help map bat activity and species distribution. The approach gives researchers data on nocturnal insect control and habitat use that would be hard to gather otherwise. Participants learn to recognize the distinct chirps produced by different microbat species during flight. The project also changes how people perceive bats once they experience the animals through sound rather than sight alone. Source: phys.org - Superconducting cables connect two quantum processors — Phys.org
Engineers linked separate quantum chips with four superconducting cables that preserve fragile quantum states across the connection. The modular approach is one path toward scaling systems beyond single-chip limits. The cables must transmit quantum information without introducing decoherence that would destroy the computational state. Researchers view this interconnection method as a practical step for building larger, distributed quantum machines. Source: phys.org
Also Today
New gel fuel improves rocket and satellite control: Phys.org A kerosene-based gel developed at Concordia University allows easier storage and flow control for propulsion systems. Source: phys.org
Family support accelerated early gene-therapy work: KOSU One family’s involvement helped move gene-therapy research forward at a critical stage. Source: kosu.org
Planetterrian Spotlight
The cholesterol study from UC San Diego stands out because the newly traced Ral-CTSA route operates separately from statin and PCSK9 targets already in use. Blocking cathepsin A left more LDL receptors intact on liver cells and cut blood LDL in the mouse model. An inhibitor previously tested for safety in people could shorten the usual timeline to a phase 2 efficacy trial. If the approach holds in humans it would give clinicians an option for patients who do not reach target levels with current drugs. What remains to be shown is whether the same CTSA inhibitor lowers LDL without new side effects when given at the doses needed for lipid control. The liver removes LDL cholesterol from circulation by capturing it at LDL receptors on hepatocyte surfaces. High dietary cholesterol gradually reduces the number of those receptors through the Ral-CTSA mechanism. This separation from existing drug targets means the pathway could address cases where statins or PCSK9 inhibitors prove insufficient. The prior Phase 1 safety data on the CTSA inhibitor provides a concrete starting point rather than requiring entirely new compound development. Further mouse work will need to confirm that receptor stabilization translates into sustained LDL reduction over longer periods.
Science Deep Dive: How bacterial toxins commandeer structural proteins
Most people assume bacterial toxins attach to signaling receptors that cells normally use to receive external messages and trigger internal responses. The toxin made by certain strains of Bacteroides fragilis instead binds claudin-4, a protein whose primary role is forming the physical seals between neighboring intestinal cells. That binding lets the toxin reach and cleave E-cadherin, the molecule that holds the gut barrier together, so the lining becomes leaky and inflamed. Every person carries this same structural protein in their colon lining, and the bacterium itself is present in about one in five healthy adults, which means the receptor the toxin exploits is already widespread. When researchers disabled the claudin-4 gene in colon epithelial cells using CRISPR, the toxin could no longer attach or cause damage, showing the protein is required for the attack. The team then built a molecular decoy that mimics the binding site and tested it in mice, where it intercepted the toxin before it reached real cell junctions. Future experiments will need to determine whether the same decoy strategy works in people without disrupting normal tight-junction function. If the decoy proves safe and effective, clinicians could gain a way to block toxin-driven colon damage without having to remove the bacterium from the gut entirely.
New findings on cell junctions and cholesterol handling show how basic biology keeps turning up fresh levers for health. |
